Novartis-backed Penn study proposes boosting CAR-T responses in CLL by waking up 'war weary' T cells

CAR-T treatments like Novartis’ Kymriah have proven effective in some B-cell-driven cancers, with one notable exception: chronic lymphocytic leukemia (CLL). Now, researchers at the University of Pennsylvania, which pioneered the CAR-T technology that formed the backbone of Kymriah, are proposing a new method for overcoming CAR-T resistance in CLL.